Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.
Biocon posts 9% rise in Q3FY26 revenue to Rs 4,173 crore; net profit jumps to Rs 143.8 crore on strong generics and ...
Biocon Ltd has completed the acquisition of OCRPS in its wholly owned subsidiaries. It bought 11.53 crore OCRPS of Biocon Biosphere Ltd for ₹115.34 crore (₹20 crore in cash, ₹95.34 crore via earlier ...
Biocon Limited has invested Rs 315,34,42,850 in its wholly owned subsidiaries Biocon Biosphere Limited and Biocon Pharma Limited through the acquisition of Optionally Convertible Redeemable ...
More recently, Mazumdar-Shaw has opened doors for KGI students in the U.S. by supporting scholarships. Late last year, Mazumdar-Shaw also hosted President Abousalem at Biocon’s headquarters in India.
Biocon’s insulin copycat aspart hit another roadblock as the FDA issued a complete response letter (CRL), saying the Malaysia production facility still must undergo a pre-approval inspection to ...
Biocon Ltd has finalised the purchase of Optionally Convertible Redeemable Non-Cumulative Preference Shares (OCRPS) from its subsidiaries for ₹315 crore.
Biocon Ltd has received US FDA approval for its complex formulation Liraglutide Injection 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda). The drug-device combination is indicated ...
Biocon said that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its complex formulation Liraglutide Injection.
Biocon Academy launches Syngene IBAB Certificate Programme in artificial intelligence in life sciences: Our Bureau, Bengaluru Thursday, March 5, 2026, 13:45 Hrs [IST] Biocon Acade ...
The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...
Biotech firm Biocon on Thursday said it has raised ₹4,150 crore through a Qualified Institutions Placement (QIP) process. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results